Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD

Abstract

To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor antagonist AZD1981 compared with placebo in patients with moderate to severe COPD. In this multicentre, randomised, double-blind, parallel-group, phase IIa study (ClinicalTrials.gov identifier: NCT00690482) patients with moderate to severe COPD received either AZD1981 1000mg twice daily or matching placebo for 4 weeks. Inhaled terbutaline was used as-needed as reliever medication throughout. The co-primary endpoints were change from baseline to end of treatment in pre-bronchodilator forced expiratory volume in 1s[FEV1] and the Clinical COPD Questionnaire (CCQ). Additional endpoints included other lung function measures, 6-minwalk test (6-MWT), COPD symptom score, reliever medication use and tolerability. 118 patients were randomised to treatment (AZD1981 n=61; placebo n=57); 83% of patients were male and the mean age was 63 years (range 43-83). There were no significant differences in the mean difference in change from baseline to end of treatment between AZD1981 and placebo for the co-primary endpoints of pre-bronchodilator FEV1 (AZD1981-placebo: -0.015, 95% CI: -0.10 to 0.070; p=0.72) and CCQ total score (difference: 0.042, 95% CI: -0.21 to 0.30; p=0.75). Similarly, no differences were observed between treatments for the other outcomes of lung function, COPD symptom score, 6-MWT, BODE index, and use of reliever medication. AZD1981 was well tolerated. There was no beneficial clinical effect of AZD1981, at a dose of 1000mg twice daily for 4 weeks, in patients with moderate to severe COPD. AZD1981 was well tolerated and no safety concerns were identified.